ANI Pharmaceuticals (ANIP) Competitors $94.79 +2.84 (+3.09%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$94.80 +0.01 (+0.01%) As of 10/17/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIP vs. ADMA, ANVS, MRUS, RNA, GRFS, CYTK, RYTM, ABVX, CRSP, and NUVLShould you be buying ANI Pharmaceuticals stock or one of its competitors? The main competitors of ANI Pharmaceuticals include ADMA Biologics (ADMA), Annovis Bio (ANVS), Merus (MRUS), Avidity Biosciences (RNA), Grifols (GRFS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), CRISPR Therapeutics (CRSP), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. ANI Pharmaceuticals vs. Its Competitors ADMA Biologics Annovis Bio Merus Avidity Biosciences Grifols Cytokinetics Rhythm Pharmaceuticals Abivax CRISPR Therapeutics Nuvalent ADMA Biologics (NASDAQ:ADMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Which has more risk & volatility, ADMA or ANIP? ADMA Biologics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Does the media refer more to ADMA or ANIP? In the previous week, ANI Pharmaceuticals had 4 more articles in the media than ADMA Biologics. MarketBeat recorded 9 mentions for ANI Pharmaceuticals and 5 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.99 beat ANI Pharmaceuticals' score of 0.94 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, ADMA or ANIP? ADMA Biologics has higher earnings, but lower revenue than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M8.04$197.67M$0.8616.70ANI Pharmaceuticals$614.38M3.35-$18.52M-$0.77-123.10 Do analysts prefer ADMA or ANIP? ADMA Biologics presently has a consensus price target of $27.67, suggesting a potential upside of 92.66%. ANI Pharmaceuticals has a consensus price target of $99.14, suggesting a potential upside of 4.59%. Given ADMA Biologics' stronger consensus rating and higher possible upside, equities analysts plainly believe ADMA Biologics is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25ANI Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.90 Do insiders & institutionals hold more shares of ADMA or ANIP? 75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 11.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is ADMA or ANIP more profitable? ADMA Biologics has a net margin of 44.06% compared to ANI Pharmaceuticals' net margin of -1.37%. ADMA Biologics' return on equity of 41.01% beat ANI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics44.06% 41.01% 28.47% ANI Pharmaceuticals -1.37%25.03%8.00% SummaryADMA Biologics beats ANI Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get ANI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIP vs. The Competition Export to ExcelMetricANI PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.06B$3.44B$6.21B$10.54BDividend YieldN/A2.28%5.70%4.80%P/E Ratio-123.1023.1685.7027.13Price / Sales3.35449.16581.70177.21Price / Cash12.4846.9237.1060.81Price / Book4.9610.4112.236.52Net Income-$18.52M-$52.77M$3.33B$276.93M7 Day Performance5.57%2.31%1.17%1.93%1 Month Performance-2.07%12.59%6.85%2.19%1 Year Performance57.17%11.18%58.93%34.62% ANI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIPANI Pharmaceuticals3.7706 of 5 stars$94.79+3.1%$99.14+4.6%+57.2%$2.06B$614.38M-123.10600News CoverageADMAADMA Biologics3.632 of 5 stars$14.07-4.0%$27.67+96.6%-9.0%$3.50B$426.45M16.36530ANVSAnnovis Bio3.1586 of 5 stars$2.25+1.1%$17.33+672.1%-78.4%$43.26MN/A-1.103MRUSMerus1.3958 of 5 stars$94.270.0%$93.12-1.2%+80.1%$7.13B$56.23M-17.1437Short Interest ↓RNAAvidity Biosciences2.5505 of 5 stars$46.18-1.7%$68.32+47.9%-5.1%$6.86B$10.90M-12.97190News CoverageInsider TradeGRFSGrifols3.7489 of 5 stars$9.61-3.4%$10.30+7.2%+11.6%$6.84B$7.81B8.2123,822CYTKCytokinetics3.8472 of 5 stars$60.64+6.4%$76.64+26.4%+6.3%$6.82B$18.47M-11.89250Trending NewsInsider TradeRYTMRhythm Pharmaceuticals2.8727 of 5 stars$97.86-1.2%$106.64+9.0%+116.9%$6.58B$130.13M-32.51140News CoverageAnalyst ForecastABVXAbivax3.4891 of 5 stars$86.67+3.3%$103.29+19.2%+787.4%$6.34BN/A0.0061Short Interest ↓High Trading VolumeCRSPCRISPR Therapeutics2.2308 of 5 stars$70.19+3.6%$71.50+1.9%+41.4%$6.16B$37.31M-12.93460Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionNUVLNuvalent2.8471 of 5 stars$83.85-0.4%$118.89+41.8%-10.8%$6.07BN/A-17.1140Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies ADMA Biologics Alternatives Annovis Bio Alternatives Merus Alternatives Avidity Biosciences Alternatives Grifols Alternatives Cytokinetics Alternatives Rhythm Pharmaceuticals Alternatives Abivax Alternatives CRISPR Therapeutics Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIP) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.